WuXi Biologics Cayman has been granted a patent for anti-CD39 antibodies that target human CD39 enzymatic activity. The patent includes specific sequences for the heavy and light chain variable regions. GlobalData’s report on WuXi Biologics Cayman gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on WuXi Biologics Cayman, Personalized cancer vaccines was a key innovation area identified from patents. WuXi Biologics Cayman's grant share as of May 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.
Anti-cd39 antibody inhibiting human cd39 enzymatic activity
A recently granted patent (Publication Number: US11970543B2) discloses an anti-CD39 antibody specifically designed to bind to human CD39. The antibody comprises a heavy chain variable region with specific complementarity determining regions (H1, H2, H3) and a light chain variable region with corresponding complementarity determining regions (L1, L2, L3). The patent further details the sequence identity requirements for the heavy and light chain variable regions, emphasizing the importance of at least 90%, 95%, or 99% sequence identity to specific sequences for the antibody's efficacy.
Moreover, the patent covers various aspects of the anti-CD39 antibody, including its classification as a monoclonal antibody or an antigen-binding fragment. It also discusses the antibody's potential forms, such as human, chimeric, humanized, or veneered antibodies, along with the inclusion of variant heavy chain constant regions like variant human IgG1, IgG2, IgG3, or IgG4 constant regions. Additionally, the patent mentions the incorporation of a wild-type human IgG heavy chain constant region and a human light chain kappa constant region in the antibody's structure. The patent also includes claims related to the antibody's sequence identity requirements, pharmaceutical compositions containing the antibody, and the specific heavy and light chain combinations necessary for its effectiveness.
To know more about GlobalData’s detailed insights on WuXi Biologics Cayman, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
